Vanguard Global Advisers
HALO icon

Vanguard Global Advisers’s Halozyme HALO Stock Holding History

Vanguard Global Advisers’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.98M Sell
50,795
-2,337
-4% -$159K ﹤0.01% 887
2026
Q1 		$3.43M Buy
+53,132
New +$3.75M ﹤0.01% 904

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vanguard Global Advisers's HALO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Halozyme (HALO) stake by 4.4% in Q2 2026, selling an estimated $159K and leaving 50,795 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Vanguard Global Advisers first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. 651 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Vanguard Global Advisers held 50,795 shares of Halozyme worth $3.98M as of Q2 2026.
  • Vanguard Global Advisers sold 2,337 Halozyme shares in Q2 2026, an estimated $159K.
  • Halozyme made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #887 holding.
  • Vanguard Global Advisers first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
  • 651 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.